Jiong Lan
Ningxia Normal University(CN)Regend Therapeutics (China)(CN)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Mechanisms and Therapy, Synthesis and biological activity, Marine Sponges and Natural Products, Synthetic Organic Chemistry Methods
Most-Cited Works
- → Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers(2014)111 cited
- → Discovery of Potent and Selective RSK Inhibitors as Biological Probes(2015)83 cited
- → Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers(2014)76 cited
- → Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies(2015)74 cited
- → Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors(2013)53 cited
- → Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors(2014)41 cited
- → Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model(2016)27 cited
- → Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors(2014)27 cited
- → 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors(2014)27 cited
- → Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target(2023)20 cited